Message #35 From:
Stock News Bot Date: December 11, 2006 06:28:00 AM
CLRI News Clearant Announces Agreement to Expand Its Direct Distribution Growth Initiative (R) to the Sports Medicine Market in the New York Region
LOS ANGELES--(BUSINESS WIRE)--Clearant, Inc. (OCTCBB:CLRI) announced today that it signed an agreement
with OR Specialties, a leading distributor of orthopedic surgical
supplies, to represent and distribute Clearant Process®
Sterile Implants for allograft sport medicine surgeries. Under the terms
of the agreement, OR Specialties will deploy its team of 13 sales
representatives to market the implants to the sports medicine
specialists through hospitals and surgery centers throughout New York,
Northern New Jersey, Connecticut and Rhode Island and Western
Massachusetts.
Over the past two years, Clearant Process®
Sterile Implants have achieved recognition and support in the sports
medicine field due to their excellent performance and superior
protection against infection. To-date, more than 9,000 patients received
a Clearant Process sterile implant with success.
“The growing recognition of the Clearant
Process® brand is opening new doors for
Clearant to reach sport medicine surgeons. To-date, Clearant does not
have any sales representation in the North East region. As a result, we
are pleased to be able to complement our direct distribution initiative
with a group of sales people as successful as those of OR Specialties.
This will, immediately, give Clearant greater market reach in the North
East region and we anticipate that this will lead to faster adoption for
the Clearant Process sterile sports medicine implants in that region.”
said Clearant Chief Executive Officer Alain Delongchamp.
“A growing number of my patients that require
ligament reconstructive surgery are good candidates for allograft
surgeries and are demanding the safest implants. Clearant helps me meet
this rising demand with a supply of sterile implants,”
commented Dr. Fred Cushner, orthopedic surgeon at the ISK Institute in
New York. “Based upon a growing body of
clinical evidence and the results that I see first-hand in patient
outcomes, Clearant’s sterile implants are the
best solution available today for virtually eliminating the risk of
infection and ensuring high-level, post-operative performance of the
tissue.”
“Each one of our 13 sales representatives has
a relationship with an average of 20 surgeons in their individual
territory thanks to our very broad product line which includes products
for several types of sport medicine surgeries such as shoulder and ACL
repair. As our sales representatives are working with nearly 100 % of
the hospital staff and approximately 260 orthopedic surgeons in our
region, we are seeing a significant demand for safer tissue.”
said Bill Tobin, OR Specialties. “We expect
that a substantial number of the surgeons we have relationships with
will become regular users of Clearant Process implants in the near term.”
“This alliance between Clearant and OR
Specialties comes in response to the growing demand for sterile
allograft tissue from orthopedic surgeons,”
said Clearant Chief Executive Officer Alain Delongchamp.
The Clearant Process is the first technology capable of eliminating all
types of pathogens in tissue implant sterilized in its final packaging,
while maintaining the integrity of the essential underlying protein in
the tissue. Products processed with the Clearant Process can achieve,
and even exceed, levels of sterility associated with medical devices.
About Clearant, Inc.
Clearant, Inc. is a leader in pathogen inactivation for biological
products. Clearant has developed the patent-protected Clearant Process,
which substantially reduces all types of bacteria and viruses in
biological products while maintaining the functionality of the
underlying tissue implant or protein. The Company began to distribute
directly to surgeons, hospitals and clinics Clearant Process sterile
implants in June 2006; in addition, Clearant continues to license the
Clearant Process and provides its patented sterilization services to
tissue banks and other biological products manufacturers. As of the end
of 1Q 2006, Clearant had 10 license and service agreements with tissue
banks. To date more than 9,000 patients have been successfully implanted
with Clearant Process sterile implants supplied by one of the Company's
licensed partners. Whereas various competing sterilization methods only
kill specific types of pathogens (such as bacteria or lipid-enveloped
viruses) for specific products, the Clearant Process reduces all types
of pathogens for products across many market segments including tissue
implants, plasma proteins, recombinant products, medical devices and
blood products. Also, the Clearant Process can be applied at various
stages of product processing and/or manufacturing, including in the
final packaging. For more information, please visit www.clearant.com.
About O.R. Specialties - Superior Surgical and Post Surgical
Products and Services
O.R. Specialties provides both surgical and post surgical products and
is a leading service provider to hospitals, surgery centers, doctor's
offices, rehab providers, and patient homes. Our headquarters are in
Port Chester, New York, and we have satellite offices throughout the
region we serve. Our surgical division is made up of tenured
professional consultants that specialize in orthopedic sports medicine,
trauma, joint replacement, and laparoscopic surgical procedures and
equipment. Our surgical teams are backed by service associates in the
field and office support in Port Chester, New York. OR Specialties' post
operative/rehab division deliver high quality products to meet the needs
of patients recovering from orthopedic injuries. Our knowledgeable sales
team works directly with surgeons and rehab providers to provide the
proper product for each patient. Our post operative sales force is
backed by an extensive team who arrange everything from insurance
billing to home delivery of products. For more information, please visit www.or-specialties.com
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in
this press release are forward looking and made pursuant to the Safe
Harbor provisions of the Private Securities Litigation Reform Act of
1995, in particular statements regarding surgeons strongly recommending
the use of implants with tissue treated by the CLEARANT PROCESS, and the
conclusions from a study by surgeons to build demand for sterilized
tissue.These forward-looking statements reflect numerous
assumptions and involve a variety of risks and uncertainties, many of
which are beyond the company's control, which may cause actual results
to differ materially from stated expectations. These risk factors
include, among others, limited operating history, difficulty in
developing, exploiting and protecting proprietary technologies, results
of additional clinical studies, acceptance and success of our direct
distribution of allografts, efficacy of the technology, intense
competition and substantial regulation in the biotechnology industry,
and additional risks discussed in the company's filings with the SEC,
available on the SEC web site http://www.sec.gov.
